ArticleEndocrine2026
Stage and age as distinct determinants of competing mortality in parathyroid carcinoma: a population-based analysis.
Article in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeParathyroid carcinoma is a rare endocrine malignancy in which much of the long-term morbidity relates to chronic hypercalcemia. Conventional survival analyses treat deaths from causes other than the cancer as censoring events, which can distort estimates of cause-specific risk. We applied competing-risk methodology to characterize cause-specific mortality and to determine whether distinct clinical factors differentially influence cancer-specific and cardiovascular/renal mortality.
methodsPatients with malignant parathyroid carcinoma (primary site C75.0) were identified from the SEER Research Data, 17 Registries, November 2023 submission (2000-2021). Cause-specific, cardiovascular/renal, and other-cause deaths were defined a priori as competing events. Cumulative incidence functions were estimated using the Aalen-Johansen estimator, compared with Gray's test, and modeled with Fine-Gray subdistribution hazard regression, adjusting for age, sex, race, and stage.
resultsAmong 656 patients (median follow-up, 86 months), 213 died: 61 (9.3%) from cancer-specific causes, 68 (10.4%) from cardiovascular/renal causes, and 84 (12.8%) from other causes. Cancer-specific mortality plateaued after roughly a decade (15-year cumulative incidence, 11.0%), whereas cardiovascular/renal mortality continued to rise (12.3%) and ultimately exceeded it. In multivariable Fine-Gray models, advanced (regional/distant) stage was independently associated with cancer-specific death (subdistribution hazard ratio [sHR], 3.37; 95% CI, 1.72-6.60) but not cardiovascular/renal death, whereas age ≥ 60 years was independently associated with cardiovascular/renal death (sHR, 2.43; 95% CI, 1.49-3.96) but not cancer-specific death.
conclusionsCancer-specific and cardiovascular/renal mortality follow distinct competing-risk trajectories in parathyroid carcinoma, with stage primarily determining cancer-specific mortality and age primarily determining cardiovascular/renal mortality. These findings support consideration of competing-risk profiles when planning long-term surveillance, including cardiovascular and renal follow-up.
Indexed as
Identifiers
42859310What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.